The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Boston Scientific Corporation (NYSE:BSX) has agreed to acquire Axonics Inc (NASDAQ: AXNX) for $71 in cash per share, representing an enterprise value of approximately $3.4 billion and an equity value ...

Medtronic is upping the ante in a patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic’s InterStim device, an implanted ...

Axonics presents with robust fundamentals and unit economics around its sacral neuromodulation segment. The company confirmed FY22 numbers above consensus, guides to FY23E revenues above the Street as ...

Shares of Axonics (NASDAQ: AXNX) were up 20.5% on Monday after the urology company agreed to be acquired by Boston Scientific (NYSE: BSX). Boston Scientific shares were also up around half a percent ...

Raymond Cohen, co-founder of Axonics, can now breathe a sigh of relief. After a long delay tied to a federal probe of the Axonics sale, Boston Scientific Corp. (NYSE: BSX) announced Nov. 15 the ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Medical technologies guidance 50 has been migrated to HealthTech guidance 554. The recommendations and accompanying content remain unchanged. This guidance replaces the NICE medtech innovation ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medtronic. The ...